SATO Corporation, Press release, 1 October 2026 at 12:00 pm

The Act on Residential Leases (AHVL) has been amended today, 1 October. Originally adopted in 1995, the amended legislation introduced changes to areas including the smoking ban, grounds for terminating a lease agreement and notice periods.

The change that has attracted the most attention in advance in terms of tenants’ everyday lives is the smoking ban. From today onwards, the ban applies to indoor areas as well as to balconies and private yards belonging to the apartment. The change also applies to lease agreements concluded before the amended legislation entered into force.

“Cigarette smoke does not stop at the boundaries of an apartment but also affects neighbours. The smoking ban aims to improve living comfort and reduce the health risks caused by cigarette smoke. At SATO, we intend to follow the principles and spirit of the Residential Leases Act, even though the law also allows landlords to make exceptions. Treating our residents equally is important to us, which is why we will not grant individual exemptions from the smoking ban,” says Olli Tång, Executive Vice President responsible for SATO’s housing business.

Landlord’s notice period changed

Landlords’ notice periods for new lease agreements has also been changed. If the tenancy has lasted for at least two years, the landlord’s notice period is four months instead of the previous six. For shorter tenancies, the notice period remains unchanged at three months. When the tenant terminates the lease agreement, the notice period continues to be one month.

As a rule, new lease agreements are initially concluded for a fixed term of 12 months, after which they will continue until further notice.

“The reform aims to strike a better balance between tenants’ and landlords’ rights regarding notice periods, which is why the landlord’s notice period has been shortened somewhat for longer tenancies. In practical terms, very little changes with 12-month fixed-term agreements, as residents don’t need to sign a new agreement or separately notify us that they wish to continue living in their home once the fixed term ends. The agreement will continue automatically,” Tång points out.

Changes help address disturbances

From today onwards, landlords will have better means to address disturbances than before. Other exceptionally serious reasons can now also constitute grounds for terminating a lease agreement.

“Social and financial difficulties have increased significantly in our society, and in the rental housing business this is reflected in payment problems and an increase in disruptive behaviour. The change in legislation gives us as landlords an important tool for dealing with challenging situations and helps safeguard neighbours’ right to peaceful, disturbance-free everyday life. Maintaining an open and confidential dialogue with tenants also makes it easier to address disturbances.”

Under the new legislation, landlords have the right to enter an apartment at a time notified to the resident in advance, even if the time of the visit cannot be agreed with the resident

“Naturally, we will continue to make every effort to visit our residents’ homes at a time that suits them. We will also notify residents of an upcoming visit well in advance, unless the situation involves safety or another exceptional circumstance requiring an urgent response.”

Read more about the changes to the Residential Leases Act and how they affect living in a SATOhome: https://www.sato.fi/en/faq-rental-apartments#ahvl

For more information, please contact:
Olli Tång, EVP, Housing Business, tel. +358 20 134 4071, olli.tang@sato.fi

Media contact:
Terhi Jokinen, Senior Communications Specialist, tel. +358 20 134 4307, terhi.jokinen@sato.fi

SATO Corporation is an expert in sustainable rental housing and one of Finland’s largest rental housing providers. SATO owns around 27,500 rental homes in the Helsinki Metropolitan Area, Tampere and Turku.

SATO aims to provide excellent customer experience and a comprehensive range of urban rental housing alternatives with good access to public transport and services. We promote sustainable development and work in open interaction with our stakeholders.

SATO invests profitably, sustainably and with a long-term view. We increase the value of our assets through investments, divestments and repairs. In 2025, SATO celebrated its 85th anniversary. www.sato.fi/en

Sanoma Learning, Press Release, 1 October 2026 at 12:00 p.m. EET

Sanoma Learning launches Sanna, an AI teacher assistant designed to reduce teachers’ workload

Co-created with more than 1,500 teachers across Europe, Sanna addresses the need for educational AI tools that reduce teachers’ workload and support increasingly diverse needs in European classrooms. Built on trusted local learning materials and national curricula, Sanna provides safe and pedagogically grounded AI support for teachers.

Sanoma Learning today launched Sanna, an AI assistant designed specifically for teachers. Sanna helps teachers prepare lessons, create additional teaching materials, provide feedback, tailor learning activities to different student needs, and save time on routine tasks. The service will be available for free trial in the Netherlands, Spain, Italy, Poland, Belgium, Finland and Sweden.

Unlike general-purpose AI tools, Sanna has been developed specifically for education, aligned with national curricula and built on Sanoma Learning’s trusted educational content and responsible AI approach. Through initial testing in 2025 and a two-month pilot programme in 2026 involving more than 1,500 teachers across Europe, the solution was further developed through direct teacher feedback, studies, and interviews to ensure it meets the needs of real classrooms.

The demand for educational AI is rising

As schools increasingly explore the use of artificial intelligence, teachers are looking for AI solutions designed for education rather than consumer use. In Sanoma Learning’s 2026 European Teacher Survey (ETS), with over 20,000 teachers responding, between 75% and 93% of teachers said AI tools used in education should be developed for educational purposes rather than adapted from general-purpose AI applications. The findings are consistent with OECD research showing that generative AI can support learning when used within clear educational frameworks and guided by sound teaching practices.

“Sanna is co-created with schools and teachers to address some of the sector’s biggest challenges. As teachers face increasing pressure to meet diverse student needs while managing growing workloads, Sanna helps save time and create personalised learning materials more efficiently, so teachers can spend more time on what matters most: supporting their students”, explains Oleg Sokolov, Senior Director of Data & AI at Sanoma Learning.

Sanna builds on Sanoma Learning’s long-standing experience in developing educational content through its local publishers and digital learning solutions for schools across Europe. By combining advances in generative AI with trusted learning materials and teaching expertise, the company aims to provide practical support that reflects the realities of today’s classrooms.

“Many teachers are already using general AI tools, while our European Teacher Survey shows that most teachers are not convinced that general-purpose AI improves pupils’ learning outcomes. They want solutions they can trust in a school setting, and that is what we are now delivering,” said Sokolov.

How Sanna works

Sanna supports teachers with everyday classroom tasks, including lesson planning, creating assignments and assessments, adapting materials for different learning levels, developing additional classroom activities, providing feedback on student assignments, and creating presentations. Teachers can use Sanna in two ways:

  • Guided tools that help create differentiated lesson materials and other teaching resources for specific educational needs.
  • An AI chat interface where teachers can ask questions, explore ideas, refine content, and generate new materials.

Teachers remain in control over teaching decisions throughout the whole process. All AI-generated content can be reviewed, edited, adapted, and approved before it is used in the classroom. Designed specifically for schools, Sanna has been developed in line with Sanoma Learning’s principles for responsible AI and educational approach.

Sanna offers a safe pedagogical environment designed to comply with EU privacy and AI regulations. Sanoma’s Responsible AI approach is based on a set of core principles that provide a coherent foundation across pedagogical, didactic, legal and ethical dimensions. For example, our educational guardrails are designed to keep AI-generated outputs relevant for learning, our product UX is designed to ensure teachers remain in control and help limit over-reliance on AI, and all data is processed within Europe.

Sanna will be available for a 30-day trial from 1 October 2026 in selected European markets. Information about availability, subscription options, and pricing can be found at www.sanna.eu.

About Sanoma Learning

Sanoma Learning is Europe’s leading K12 learning company, serving about 25 million students across our markets. We support teachers and students with best-in-class learning content and solutions to help all students reach their potential.

Our blended offering combines printed and digital learning materials, digital platforms, and AI-driven solutions purpose-built for learning and teaching. We develop our learning materials and solutions in close collaboration with teachers and students to truly understand their needs and aspirations.

By combining deep pedagogical expertise with high-quality content, innovative technology and responsible use of AI, we create positive impact and help shape the future of K12 education.

Sanoma Learning is part of Sanoma, an innovative and agile learning and media company. Through learning and media, we have a positive impact on the lives of millions of people every day.

For more information about Sanoma Learning, visit our website: sanomalearning.com.

Resources

OECD (2026), OECD Digital Education Outlook 2026: Exploring Effective Uses of Generative AI in Education, OECD Publishing, Paris, https://doi.org/10.1787/062a7394-en.

Sanoma Learning (2026), 2026 European Teacher Survey: Education in evolution: Teachers are ready for AI but only when it is built for learning. Sanoma, Helsinki, Finland. https://www.sanomalearning.com/en/our-solutions/european-teacher-survey/

Sanna: www.sanna.eu

Contact information:

Johnny Anderson

Communication Director, Sanoma Learning
+47 932 40 192
Johnny.anderson@sanoma.com
communications@sanomalearning.com

The delivery forms part of a major Dutch hydrogen innovation project, supported by the EU, to help assess lower-emission solutions for heavy-duty materials handling applications

Hyster hydrogen fuel cell ReachStacker at Rotterdam Shortsea Terminals

The Hyster RSJ46-33XDH/62 ReachStacker on site
The Hyster RSJ46-33XDH/62 ReachStacker on site

ROTTERDAM, NETHERLANDS, Oct. 01, 2026 (GLOBE NEWSWIRE) — Hyster announces the delivery of a hydrogen fuel cell-powered ReachStacker to Rotterdam Shortsea Terminals (RST) in the Netherlands as part of a joint initiative exploring the role of hydrogen in the future of port and logistics decarbonization.

The Hyster RSJ46-33XDH/62 ReachStacker will support operations in Europe’s largest dedicated shortsea shipping hub, primarily handling 45-foot containers, including open-top containers. To support these requirements, it is equipped with a specialized 45-foot spreader and is powered by a Nuvera 60-kilowatt fuel cell engine that converts hydrogen into electricity to support a 130-kilowatt-hour lithium-ion battery. It also incorporates the standardized Hyster software architecture used across other Hyster electric products, helping to provide a common operator experience, diagnostics platform and service approach.

“Ports and terminals are under increasing pressure to lower emissions without compromising performance,” explains Lucien Robroek, President, Global Big Trucks, Hyster. “Hydrogen fuel cell technology has the potential to play an important role in applications where equipment must combine zero tailpipe emissions with the power and uptime required for intensive container handling. Working alongside RST and the wider project team will help further our understanding of how this technology can support the future needs of the industry.”

The ReachStacker has been supplied by Hyster and local authorized Hyster dealer Heffiq as part of a five-year innovation project supported by the Province of South Holland and the Just Transition Fund (JTF). Rotterdam Shortsea Terminals, Berkman Energie Services, Hyster, STC Next and HarbourHUB are joining forces within the JTF program to make port logistics more sustainable. Together, they are developing a unique field lab in which two key innovations will be demonstrated: a modular hydrogen refueling station and a hydrogen-powered ReachStacker developed in the Netherlands.

This living lab demonstrates how hydrogen can be effectively integrated into logistics and industrial processes independently of the electricity grid. The ReachStacker deployment will also enable RST to gain practical operational experience with hydrogen-powered container handling equipment in its demanding port environments.

“For us, sustainability is not just an ambition for the future; it is about the choices we make today,” says Arno Storm, CEO, RST. “This hydrogen refueling station and hydrogen fuel cell-powered ReachStacker allow us to explore the transition in practice. We want to play our part, learn along the way and contribute to a cleaner and more sustainable future for the generations to come.”

Local authorized dealer Heffiq will support the ReachStacker through its established service infrastructure and expertise in port and terminal applications, while Hyster experts will work alongside the dealer and customer throughout the project.

“RST has been a valued Heffiq and Hyster customer for many years, and we are proud to support them on this next step in their sustainability journey,” says Martijn Veerkamp, Commercial Director, Heffiq. “Projects like this depend on strong collaboration between customers, technology providers and service partners. By combining our local expertise with Hyster innovations and RST’s operational knowledge, we have been able to deliver a pioneering solution that will generate meaningful insights by working in a live terminal environment.”

The partners in the JTF program are investing in human capital as well as technological innovation. In a joint experience center, employees, students and logistics professionals will be trained for the energy transition and in the safe and efficient use of hydrogen. The project, which is co-funded by the European Union, directly contributes to carbon dioxide reduction, future regulations and standardization, and a better energy balance within ports. In doing so, it provides a powerful impetus for the sustainable transformation of port logistics in Rotterdam and beyond.

“South Holland is at the forefront of the energy transition, and innovative projects like this hydrogen fuel cell-powered ReachStacker keep us there,” said Jeroen van Dijken, South Holland Provincial Executive. “We are creating opportunities to accelerate innovation by bringing together pioneering companies, educational institutions and public partners. This strengthens our regional economy and prepares our workforce for the industries of the future. The knowledge gained through this initiative will reinforce South Holland’s position as a leading hub for sustainable logistics and clean energy development.”

For more information, visit www.hyster.com.

Images
For images and a logo, click here.

ABOUT HYSTER
Hyster is a leading worldwide provider of Hyster® forklift truck and container handling solutions for the toughest, most intense industries on earth. The company designs and manufactures an industry leading, comprehensive range of material handling equipment, meeting the unique demands of everything from fast-paced industrial warehouses and manufacturing facilities to the most demanding, heavy-duty applications like ports and terminals. Backed by a dedicated, global dealer network and nearly a century of material handling experience, Hyster is the trusted resource customers can count on for technology tough enough for their worksites and proven solutions that keep critical operations moving.

Hyster Company is a division of Hyster-Yale Materials Handling, Inc., a wholly owned subsidiary of Hyster-Yale, Inc. (NYSE:HY) which is headquartered in Cleveland, Ohio and operates globally.

©2026 Hyster-Yale Materials Handling, Inc., all rights reserved. Hyster is a trademark of Hyster-Yale Materials Handling, Inc.

Attachment

CONTACT: Jennifer Timblin
Hyster
252-412-4322
jennifer.timblin@hyster-yale.com

Jude Mitcham
Molokini Marketing Ltd
+44 (0) 1903 207408
jude@molokini.co.uk

Appointments Strengthen Support for Clients Facing Financial Distress, Liquidity Challenges and Complex Transactions

LONDON and LEEDS, United Kingdom, Oct. 01, 2026 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of James Bulloss, Kasey Lin, Theo Kitsanelis and Matthew Mansell-Ahmed as Managing Directors within the firm’s Corporate Finance segment, further strengthening its Turnaround & Restructuring capabilities across the UK.

“When businesses face financial pressure, disruption or uncertainty, getting the right advice at the right time can make a real difference to the outcome,” said Matt Callaghan, Head of UK Turnaround & Restructuring at FTI Consulting. “Our reputation in restructuring and insolvency is built on deep technical expertise and a pragmatic, commercial approach that helps clients achieve the best possible result. James, Kasey, Theo and Matthew bring complementary expertise across turnaround, restructuring and restructuring tax. Their arrival adds further depth to our teams in London and Leeds, enabling us to deploy an even broader range of experts on mandates across the UK.”

Mr. Bulloss, who is based in Leeds, joins FTI Consulting from PwC, where he was a Director in the Business Restructuring practice. He brings more than 18 years of experience advising on restructurings, insolvencies and distressed M&A transactions across a range of industries. In his role at FTI Consulting, he will support corporations, private lenders and financial institutions at every stage of the distress cycle, from early-stage financial reviews and value protection strategies to distressed M&A, investments and formal insolvencies.

Ms. Lin, who is based in London, previously was a Vice President in the Financial Restructuring practice at Houlihan Lokey. She brings expertise in cross-border restructurings and distressed situations across a variety of sectors, including real estate, telecoms, healthcare and retail. In her role at FTI Consulting, Ms. Lin will provide capital structure analysis and advise debtors and creditors on restructurings, liability management transactions and distressed M&A.

Mr. Kitsanelis, who is based in London, was most recently a Senior Vice President at Seabury Capital. He brings deep expertise in the global aviation sector, having guided airlines and key stakeholders through complex restructurings and corporate transactions. At FTI Consulting, he will join the Aviation practice, where he will draw on his experience in high-stakes engagements to advise clients on strategic initiatives and distressed situations.

Mr. Mansell-Ahmed, who is based in London, formerly was an Associate Director in the Financial Advisory practice at Teneo. His expertise includes tax due diligence and structuring advice for restructurings, refinancings and insolvencies. In his role at FTI Consulting, Mr. Mansell-Ahmed will provide tax planning support across a range of situations and transactions to optimise business decisions and investments.

These appointments are part of FTI Consulting’s continued investment in its Turnaround & Restructuring practice across the UK, complementing the recent additions of Chris Hawes in London and Matt McErlane and Emma Lister in Leeds. Together with the opening of FTI Consulting’s Leeds office in June and its established team in Manchester, they enhance the firm’s ability to support clients managing financial stress or distress nationwide.

About FTI Consulting
FTI Consulting, Inc. is a leading global expert firm for organisations facing crisis and transformation, with more than 8,100 employees located in 32 countries and territories as of June 30, 2026. In certain jurisdictions, FTI Consulting’s services are provided through distinct legal entities that are separately capitalised and independently managed. The Company generated $3.8 billion in revenues during fiscal year 2025. More information can be found at www.fticonsulting.com.

FTI Consulting, Inc.
200 Aldersgate
Aldersgate Street
London, EC1A 4HD

Investor Contact:
Mollie Hawkes
+1.617.747.1791
mollie.hawkes@fticonsulting.com

Media Contact:
publicrelations@fticonsulting.com

Ress Life Investments
Nybrogade 12
DK-1203 Copenhagen K
Denmark
CVR nr. 33593163
www.resslifeinvestments.com

To: Nasdaq Copenhagen
Date: 1 October 2026

Corporate Announcement 34/2026

Ress Life Investments A/S publishes Net Asset Value (NAV).

Ress Life Investments A/S publishes the Net Asset Value (NAV) per share as of 15 September 2026.

NAV per share in USD: 2748.58

The performance during the first half of September is -0.06% in USD. The year-to-date net performance is 4.17% in USD.

Assets under management (AUM) are 227.6 million USD.     

The NAV per share in EUR is published on the website of Nasdaq Copenhagen under the section AIF Companies and Funds, where the bid and ask prices are published. The daily NAV in EUR is calculated as the most recently published NAV in USD divided by the European Central Bank’s EUR/USD reference rate on the relevant day.

Questions related to this announcement can be made to the company’s AIF-manager, Finserve Nordic AB.

Contact person:
Gustaf Hagerud
gustaf.hagerud@finserve.se
Tel + 46 73 660 72 42

Note: The terms for subscription of shares, minimum subscription amount and redemption of shares are provided in the Articles of Association, Information Brochure and in the Key Information Document available on the Company’s website, www.resslifeinvestments.com.

Attachment

Company announcement – No. 52 / 2026

Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes

  • In the SYNCHRONIZE-2 trial, which met its co-primary endpoints, participants achieved significant body weight reduction of up to 13.1% versus 3.1% in the placebo arm, after 76 weeks of treatment with survodutide in people with type 2 diabetes, a population in which weight loss is typically more challenging.1
  • Detailed results from the Phase III trial indicate survodutide improves key markers of cardiometabolic health, including a reduction of up to 1.21% in HbA1c from a baseline of 7.4%, alongside improvements in waist circumference and insulin sensitivity, building on evidence of its potential to address the underlying metabolic drivers of obesity and type 2 diabetes.1
  • These results were presented today at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) and simultaneously published in The New England Journal of Medicine, with new findings from a body composition sub study of SYNCHRONIZE-1 also being presented.1,2,3

Copenhagen, Denmark, October 1, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that Boehringer Ingelheim has reported positive results from the Phase III SYNCHRONIZE-2 trial, which investigates the glucagon/GLP-1 receptor dual agonist survodutide (BI 456906) in adults living with obesity or overweight and type 2 diabetes (T2D).1 The trial met its co-primary endpoints, which were % change in body weight from baseline and body weight reduction of ≥5% from baseline, using both the treatment-regimen* and efficacy estimands†.1 After 76 weeks of treatment with survodutide, sustained weight loss of up to an average of 13.1% was seen using the efficacy estimand, a statistically significant decrease versus 3.1% in the placebo arm (p<0.0001)‡.1 The trial also met its other co-primary endpoint, with up to 79.3% of adults treated with survodutide achieving a body weight reduction of ≥5%, using the efficacy estimand, versus 32.7% in the placebo arm (p<0.0001).1 Full SYNCHRONIZE-2 results were presented today at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) and simultaneously published in The New England Journal of Medicine.1,2

“We are very encouraged by the SYNCHRONIZE-2 results reported today by Boehringer Ingelheim, demonstrating the potential of survodutide in people living with obesity and type 2 diabetes, by providing both meaningful weight loss and glycemic control. The results reported today add to the growing body of evidence from the broad SYNCHRONIZE program, further reinforcing the novel mechanism of survodutide and its ability to potentially address not only obesity, but also the underlying disease drivers and associated metabolic health consequences,” said David Kendall, MD, Chief Medical Officer of Zealand Pharma. “We remain encouraged by Boehringer Ingelheim’s commitment to bring survodutide to patients living with overweight or obesity and associated metabolic dysfunction and look forward to SYNCHRONIZE-CVOT results later this year.”

Beyond weight loss, key secondary endpoint results showed that adults treated with survodutide experienced improvements in important cardiometabolic health markers.1 This included a significant improvement in blood sugar control, with participants experiencing a reduction of up to 1.21% in HbA1c using the efficacy estimand, compared with a 0.03% reduction in the placebo arm (p<0.0001) from 7.4% HbA1c at baseline.1 Additionally, those receiving survodutide showed significant reductions in waist circumference – a clinical marker closely linked to visceral fat and cardiometabolic risk, of 11.1 cm using the efficacy estimand versus a reduction of 3.5 cm in the placebo arm (p<0.0001).1,4 Insulin sensitivity was also seen to improve, evidenced by reduction in fasting glucose and favorable changes in insulin resistance (HOMA-IR) and insulin secretion (HOMA-β) versus placebo. More people on survodutide reverted to normoglycemia (HbA1c<5.7%) during their treatment period than on placebo (up to 29.5% vs 4.0% on placebo, efficacy estimand).1 Together, these findings demonstrate the potential of glucagon/GLP-1 dual agonism to improve metabolic health, including glycemic control, in people living with obesity and T2D.1

“Obesity and type 2 diabetes are deeply intertwined, with excess weight increasing the risk of T2D. For people living with these conditions, sustained weight loss is often a biological struggle rather than a lack of willpower,” said Dr. Sean Wharton, M.D., PharmD, Coordinating Investigator of the SYNCHRONIZE-2 trial. “These results are encouraging because, in obesity medicine, clinicians increasingly recognize the opportunity to address multiple interconnected health conditions together. Seeing improvements in glycemic control and insulin sensitivity alongside weight loss provides evidence that tackling obesity can positively influence broader metabolic health. This brings new optimism to people seeking more effective ways to improve their overall health.”

T2D and obesity are interrelated metabolic conditions, with the liver playing a central role in disease progression.5,6 Survodutide, an investigational glucagon/ GLP-1 receptor (GCGR) dual agonist, is designed to target multiple underlying metabolic drivers by improving glycemic control, reducing appetite, and supporting reductions in liver fat.7,8,9 Notably, while glucagon is traditionally associated with raising blood glucose, survodutide’s dual mechanism may help improve insulin sensitivity and glucose management through its effects on liver fat reduction.7,10 This novel approach challenges conventional understanding of glucagon biology, suggesting that the specific balance of GCGR and GLP-1R agonism may help preserve glycemic control. Survodutide has not been approved for use, and its efficacy and safety have not been established.

“The growing body of evidence from our SYNCHRONIZE Phase III program continues to strengthen our understanding of survodutide’s potential in people living with obesity, including those with type 2 diabetes. The SYNCHRONIZE-2 results demonstrate meaningful weight loss alongside improvements in glycemic control and other key markers of metabolic health, reinforcing our belief that obesity should be addressed as a complex chronic disease with interconnected health consequences,” said Shashank Deshpande, Chairman of the Board of Managing Directors and Head of Human Pharma, Boehringer Ingelheim. “We remain committed to advancing innovative treatment approaches that address the diverse needs of people living with obesity across different stages of disease and risk profiles.”

As expected with GLP-1 based therapies and in line with previously reported survodutide trials, in SYNCHRONIZE-2 the most commonly reported adverse events for survodutide were gastrointestinal (GI) events, which were mostly mild to moderate in severity.1 The more frequent events included nausea, vomiting, diarrhea, and constipation.1 The treatment discontinuation rates due to GI adverse events were 18% in people treated with survodutide compared to 1.2% in the placebo arm.1

Discontinuations usually occurred during the dose escalation phase, as the study protocol allowed limited flexibility to manage adverse events.1 Current and upcoming trials allow for more flexible, patient‑centered titration strategies to support tolerability.11,12

Additional analyses from a sub study in the SYNCHRONIZE-1 trial in people living with obesity without T2D (n=75) were presented alongside the SYNCHRONIZE-2 results.3 MRI-based body composition assessments further reinforced the fat-targeting profile of survodutide, demonstrating preferential reductions in metabolically active visceral and liver fat.3 The overall pattern of body composition change suggests a favorable shift away from excessive accumulation of fat around the abdomen.3 Building on previously reported lean mass findings,13 a new muscle-specific analysis showed that muscle accounted for no more than 10% of total tissue lost.3 Importantly, reductions in visceral and liver fat appear largely independent of the degree of weight reduction achieved, suggesting that these benefits may extend beyond weight reduction alone.3

Together, the SYNCHRONIZE findings suggest survodutide may help address multiple dimensions of metabolic dysfunction, delivering weight loss and glycemic improvements while reducing harmful visceral and liver fat. Furthermore, adipose tissue reduction was shown to be greater than the loss of lean body mass, indicating that the majority of body weight reduction was attributable to the loss of adipose tissue.13

Boehringer Ingelheim has a broad survodutide development program, which spans obesity and related metabolic conditions, MASH and T2D.11,12,14,15,16,17,18,19,20 Boehringer Ingelheim expects to present results from its cardiovascular outcomes trial (SYNCHRONIZE-CVOT) later this year, which will further elucidate survodutide’s cardiovascular safety profile and strengthen understanding of its role within the broader cardiometabolic disease continuum.17 Additionally, Boehringer launched the Phase III SYNCHRONIZE-T2D (NCT07754461) trial to further investigate the effect of survodutide on improving glycemic control in adults with T2D who are managing their condition with diet and exercise alone or in combination with diabetes medications, including insulin.20

This company announcement discloses inside information pursuant to Article 17 of the Market Abuse Regulation (EU) No 596/2014.

About obesity and overweight
More than one billion people around the world are living with obesity today (1 in 8 of us) – and by 2030, that number could be more than double what it was in 2010.21 Overweight and obesity are complex chronic conditions involving abnormal or excessive fat accumulation that present a risk to a person’s overall health.22

About survodutide (BI 456906) 
Survodutide is a glucagon/GLP-1 receptor dual agonist that activates both the glucagon and GLP-1 receptors, which play a role in controlling metabolic functions.7,9,23 Survodutide is an investigational agent and has not been approved for use; its efficacy and safety has not been established. It is being evaluated in a robust Phase III clinical development program, including the SYNCHRONIZE studies for people living with overweight or obesity,14,15,16,17,18,19 the LIVERAGE studies for people living with MASH and fibrosis,11,12 and SYNCHRONIZE T2D for adults with T2D.20

Survodutide has potential to treat adults with non-cirrhotic MASH and moderate or advanced fibrosis (stages 2 or 3) and has been recognized by the U.S. FDA, which granted it: 

  • Fast Track designation in May 2021 and;24
  • Breakthrough Therapy designation in September 2024.25

Survodutide’s potential to treat adults with MASH and fibrosis has also been recognized by: 

  • the European Medicines Agency (EMA), through acceptance to its PRIME scheme in November 2023 and;26
  • the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) which granted it Breakthrough Therapy designation in June 2024 and;
  • the Taiwan Food and Drug Administration which granted it Breakthrough Designation in September 2024.

Survodutide is licensed to Boehringer Ingelheim from Zealand Pharma, with Boehringer solely responsible for development and commercialization globally. Survodutide is part of Boehringer Ingelheim’s research and development portfolio in the cardiovascular, renal and metabolic disease areas.

About the SYNCHRONIZE-2 trial (NCT06066528)
This is a Phase III, double-blind, placebo-controlled 76-week efficacy and safety trial of survodutide among 755 adults living with obesity or overweight and type 2 diabetes.15 Participants received a weekly injection of survodutide at either a 3.6 mg or 6.0 mg dose, or placebo.15 The co-primary endpoints of the trial are the percentage change in body weight from baseline to Week 76, and an achievement of body weight reduction ≥5% from baseline to Week 76.15

There are 22 secondary endpoints, including, achievement of ≥10, ≥15%, and ≥20% body weight reduction, and absolute changes from baseline to Week 76 in:15

  • Body weight
  • Glycosylated hemoglobin A1c (HbA1c)
  • Waist circumference
  • Blood pressure
  • Eating Behavior PRO
  • Body Mass Index (BMI)
  • Fasting plasma glucose (FPG)

About the SYNCHRONIZE program 
Survodutide has been evaluated in three other global Phase III studies for people living with overweight or obesity.

  • SYNCHRONIZE-1 enrolled adults without type 2 diabetes.14
  • SYNCHRONIZE-MASLD enrolled adults with a confirmed or presumed diagnosis of MASH.16
  • SYNCHRONIZE-CVOT enrolled adults with cardiovascular disease, chronic kidney disease, or with risk factors for cardiovascular disease.17

Survodutide has also been explored in two Phase III in-market trials:

  • SYNCHRONIZE-JP in Japan and SYNCHRONIZE-CN in China are exploring survodutide for sub-populations of people living with obesity.18,19 SYNCHRONIZE-JP explores the relative change in liver fat and body composition parameters from baseline to Week 76 when treated with survodutide versus placebo, as a secondary endpoint.18

As part of the broader evidence program, a set of Phase IIIb studies are being advanced to address key unmet needs in people living with obesity and real-world care, including:

  • SYNCHRONIZE-HERA will evaluate survodutide in women’s health.
  • ELEVATE-LIVER will assess the impact of survodutide in the preservation of cardiac function and structure in people living with metabolic dysfunction-associated steatotic liver disease (MASLD) or early metabolic dysfunction-associated steatohepatitis (MASH).
  • SYNCHRONIZE-START will examine real-world titration approaches, including treatment initiation and switching from GLP-1 RAs, with a focus on tolerability.

About SYNCHRONIZE-T2D
SYNCHRONIZE-T2D will investigate the effect of survodutide on improving glycemic control in adults with T2D who are managing their condition with diet and exercise alone or in combination with diabetes medications, including insulin.20

About LIVERAGE and LIVERAGE-Cirrhosis 
LIVERAGE and LIVERAGE-Cirrhosis are global Phase III clinical trials investigating the efficacy and safety of survodutide in adults with MASH and fibrosis stages 2 or 3 and in those with compensated MASH cirrhosis (fibrosis stage 4), respectively.11,12

LIVERAGE will enroll approximately 1,800 adults, and LIVERAGE-Cirrhosis will enroll approximately 1,590 adults. In each trial, participants are randomized to receive weekly injections of either survodutide, reaching a maximum dose, or placebo.11,12

About Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,300 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at www.boehringer-ingelheim.com/uk (UK and Ireland) or www.boehringer-ingelheim.com (rest of world).

*The treatment-regimen estimand is the estimated treatment effect, regardless of whether the patient adheres to the treatment, discontinues, or initiates other therapies.

†The efficacy estimand is the estimated treatment effect assuming patients remained on treatment for the entire study duration.

‡P-values for efficacy estimand are nominal.

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data‑driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health.

To date, more than ten Zealand Pharma‑invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization.

Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com.

Forward-looking statements
This company announcement contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995 in the United States, as amended, even though no longer listed in the United States this is used as a definition to provide Zealand Pharma’s expectations or forecasts of future events regarding the research, development, and commercialization of pharmaceutical products, the timing of the company’s clinical trials and the reporting of data therefrom and the company’s significant events and potential catalysts in 2026 and financial guidance for 2026. These forward-looking statements may be identified by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,” “potential,” “will,” “would”, and other words and terms of similar meaning. You should not place undue reliance on these statements, or the scientific data presented. The reader is cautioned not to rely on these forward-looking statements. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect, and which include, but are not limited to, unexpected costs or delays in clinical trials and other development activities due to adverse safety events or otherwise; unexpected concerns that may arise from additional data, analysis or results obtained during clinical trials; our ability to successfully market both new and existing products; changes in reimbursement rules and governmental laws and related interpretation thereof; government-mandated or market-driven price decreases for our products; introduction of competing products; production problems; unexpected growth in costs and expenses; our ability to effect the strategic reorganization of our businesses in the manner planned; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; regulatory authorities may require additional information or further studies, or may reject, fail to approve or may delay approval of our drug candidates or expansion of product labelling; failure to obtain regulatory approvals in other jurisdictions; exposure to product liability and other claims; interest rate and currency exchange rate fluctuations; unexpected contract breaches or terminations; inflationary pressures on the global economy; and political uncertainty. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. All such forward-looking statements speak only as of the date of this press release/company announcement and are based on information available to Zealand Pharma as of the date of  this release/announcement. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice.
Zealand Pharma® is a registered trademark of Zealand Pharma A/S. 

Contacts
Eric Rojas (Investors)
Vice President, Head of Investor Relations
erojas@zealandpharma.com

Neshat Anis Ahmadi (Investors)
Manager, Investor Relations
neahmadi@zealandpharma.com

Rachel James-Owens (Media)
Vice President, Corporate Communications & Media Relations
RJamesOwens@zealandpharma.com

Andreas Hylleberg (Media)
Director, External Communications
 AHylleberg@zealandpharma.com

Amber Fennell, Jessica Hodgson, Sean Leous (Media)
ICR Healthcare
 ZealandPharma@icrhealthcare.com
+44 (0) 7739 658 783

References

  1. Wharton, S. “Efficacy and safety of survodutide, a novel GCG/GLP-1 receptor dual agonist, for treatment of people with obesity and T2D: primary data from the SYNCHRONIZETM-2 trial” Oral presentation at the European Association for the Study of Diabetes (EASD) 2026, Milan, Italy. 1 October 2026.
  2. Wharton S, le Roux CW, Startseva E, et al. Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes. N Engl J Med 2026; DOI: 10.1056/NEJMoa2607219
  3. Pietiläinen, K. “Metabolic benefits of glucagon receptor/GLP-1 receptor dual agonism beyond weight reduction: additional insights from the SYNCHRONIZETM-1 phase 3 clinical trial” Oral presentation at the European Association for the Study of Diabetes (EASD) 2026, Milan, Italy. 1 October 2026.
  4. Ness-Abramof R, Apovian CM. Nutr Clin Pract. 2008 Aug-Sep;23(4):397-404.
  5. Ndumele C, et al. Circulation. 2023;148(20):1606-1635.
  6. Handelsman Y, et al. Metabolism. 2024;159:155931.
  7. Arun A, et al. Cardiology in Review. Survodutide: A Dual GLP-1/Glucagon Agonist Reshaping Cardiometabolic Care [Internet]. Available from: https://journals.lww.com/cardiologyinreview/abstract/9900/survodutide__a_dual_glp_1_glucagon_agonist.598.aspx. Last accessed: September 2026.
  8. Shah M, Vella A. Rev Endocr Metab Disord. 2014;15(3):181-187.
  9. Sanyal AJ, et al. N Engl J Med. 2024;391(4):311-319.
  10. Jiang G, Zhang BB. Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab. 2003 Apr;284(4):E671-8.
  11. Clinicaltrials.gov. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis. Available at: https://clinicaltrials.gov/study/NCT06632444. Last accessed: September 2026.
  12. Clinicaltrials.gov. LIVERAGE™ – Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis. Available from: https://clinicaltrials.gov/study/NCT06632457. Last accessed: September 2026.
  13. Le Roux CW, et al. Survodutide Once Weekly for the Treatment of Adults with Obesity. The New England Journal of Medicine. 2026. doi: 10.1056/NEJMoa2600751. Last accessed: September 2026.
  14. Clinicaltrials.gov. A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight (SYNCHRONIZE™-1). Available at: https://clinicaltrials.gov/study/NCT06066515. Last accessed: September 2026.
  15. Clinicaltrials.gov. A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight (SYNCHRONIZE™-2). Available at: https://clinicaltrials.gov/study/NCT06066528. Last accessed: September 2026.
  16. Clinicaltrials.gov. A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight. Available at: https://clinicaltrials.gov/study/NCT06309992. Last accessed: September 2026.
  17. Clinicaltrials.gov. A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ – CVOT). Available at: https://clinicaltrials.gov/study/NCT06077864. Last accessed: September 2026.
  18. Clinicaltrials.gov. A Study to Test Whether BI 456906 Helps Japanese People Living With Obesity Disease (SYNCHRONIZE™JP). Available at: https://clinicaltrials.gov/study/NCT06176365. Last accessed: September 2026.
  19. Clinicaltrials.gov. A Study to Test Whether BI 456906 Helps Chinese People Living With Overweight or Obesity to Lose Weight. Available at: https://clinicaltrials.gov/study/NCT06214741. Last accessed: September 2026.
  20. Clinicaltrials.gov. A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar. Available at: https://clinicaltrials.gov/study/NCT07754461. Last accessed: September 2026.
  21. World Heart Federation. Obesity. 2015. Available at: https://world-heart-federation.org/what-we-do/obesity. Last accessed September 2026.
  22. Bray A, et al. Obes Rev 2017;18:715-723.
  23. Novikoff A. Peptides 2023; 165:171003.
  24. “Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH.” Boehringer Ingelheim. Available at: www.boehringer-ingelheim.com/us/press-release/boehringer-ingelheim-and-zealand-pharma-receive-fda-fast-track-designation. Last accessed: May 2026.
  25. Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide. Boehringer Ingelheim. Available at: www.boehringer-ingelheim.com/human-health/metabolic-diseases/survodutide-us-fda-breakthrough-therapy-phase-3-trials-mash. Last accessed: May 2026.
  26. “List of medicines currently in PRIME scheme.” European Medicines Agency. December 2023. Available at: www.ema.europa.eu/en/documents/other/list-medicines-currently-prime-scheme_en.xlsx. Last accessed: September 2026.

Attachment

Transaction expected to approximately double Inseego’s revenue and expand its global footprint across Europe, the Middle East, Asia, Oceania, and the Americas

SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) — Inseego Corp. (NASDAQ: INSG) today announced the completion of its acquisition of Nokia’s Fixed Wireless Access (FWA) business, first announced on April 30, 2026.

The acquisition is expected to approximately double Inseego’s revenue and position the company as a global wireless broadband leader. By adding indoor, outdoor and millimeter-wave FWA solutions to its wireless broadband portfolio, Inseego expands its reach across consumer and business connectivity. The transaction also extends Inseego’s footprint to carriers across Europe, the Middle East, Asia, Oceania, and the Americas; and significantly expands its engineering capabilities.

Following the transaction, approximately 250 people associated with the acquired business will support Inseego’s expanded operations across engineering, product management, supply chain and sourcing, and customer support. This group includes employees joining Inseego and Nokia personnel who will continue to support the business under a transition services agreement.

To support its expanded global operations, Inseego has established an international headquarters in Amsterdam and a development center in Athens, expanded its presence in Bangalore, and added customer-facing sales and technical resources across its new markets.

“With the acquisition complete, Inseego enters its next chapter as the global wireless broadband leader,” said Juho Sarvikas, CEO of Inseego. “We now have the scale, technology, and global reach to support carriers across business, residential, and mobile use cases.”

Under the terms of the acquisition and Nokia’s $10 million cash investment in Inseego, also completed today, Nokia received an equity ownership stake in Inseego in the form of approximately 1.9 million shares of Inseego common stock, representing an approximately 11% ownership interest. Nokia also received warrants to purchase an aggregate up of to approximately 0.8 million shares of common stock, at an exercise price of $4.26 per share.

In addition to the previously-announced terms of the acquisition, Nokia will also be providing a $10 million cash payment to Inseego by October 15, 2026 in support of Inseego’s engineering investment to drive the interoperability of its device OS and cloud platform with certain of Nokia’s technology ecosystems over the coming year.

Inseego and Nokia have designed their partnership to ensure continuity for existing customers and support for future growth. Nokia will provide support through the transition and refer new FWA opportunities to Inseego, including those where FWA is part of broader Nokia network deployments; considering the aim of delivering the outcomes that best serve customer interests and requirements.

The relationship will also extend to technology collaboration across AI-RAN, converged fiber and 5G connectivity, end-to-end network optimization and distributed edge computing. Together, the companies will explore how Nokia’s network infrastructure and Inseego’s intelligent edge solutions can advance AI-driven networking and the wireless edge.

“This is an important milestone for our customers, our teams, and both companies,” said Konstanty Owczarek, Chief Corporate Development Officer at Nokia. “Inseego brings the focus and expertise to take the FWA business forward. Our continued collaboration brings together our technologies and capabilities that can deliver greater value for our customers.”

To learn more about this transaction and the resulting portfolio, visit https://www.inseego.com/welcoming-nokias-fwa-business-to-inseego/.

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this communication may be characterized as forward-looking under the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks, uncertainties, and other factors that could cause actual results to differ materially. Statements in this communication that are forward-looking may include statements regarding: : (1) the anticipated benefits to, or impact of, the acquisition of Nokia’s Fixed Wireless Access business on Inseego’s business; (2) expectations for Inseego following the closing of the acquisition, including the effect of the acquisition on Inseego’s revenues, product portfolio, customer relationships, global operations, engineering capabilities and strategic relationship with Nokia; (3) expected customer continuity, future growth opportunities, go-to-market activities, interoperability testing, technology collaboration and innovation initiatives; and (4) any statements preceded by or including “continue,” “expect,” “will,” “may,” “plan,” “intend,” “believe,” “anticipate,” “explore,” “opportunity” or similar expressions. These forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond Inseego’s control, and are based on management’s best assumptions and beliefs in light of the information currently available to Inseego. Risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements include: (1) possible disruption related to the acquisition to current plans, operations and business relationships, including through the loss of customers, suppliers, partners or employees; (2) the ability to recognize the anticipated benefits of the acquisition, including customer continuity, expanded market opportunities, technology collaboration and future revenue growth; (3) the risk that Inseego will not be able to integrate the acquired business successfully or realize anticipated synergies when expected, or at all; (4) the amount of costs, fees, expenses and other charges incurred by Inseego related to the acquisition and integration; (5) the possible diversion of management’s time and attention from ongoing business operations and opportunities; (6) the response of customers, suppliers, partners, competitors and other market participants to the acquisition; (7) potential litigation or regulatory developments relating to the acquisition; and (8) the other risks and uncertainties detailed in the periodic reports that Inseego files with the SEC. All forward-looking statements in this communication are based on information available to Inseego as of the date of this communication, and, except as required by law, Inseego assumes no obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

About Inseego

Inseego is a global leader in wireless broadband, delivering fast, reliable connectivity to homes, businesses, and people on the move. With the acquisition of Nokia’s FastMile fixed wireless access product, Inseego offers one of the industry’s broadest cellular broadband portfolios, spanning fixed wireless gateways, mobile hotspots and routers, enterprise and industrial gateways, and cloud-based device, network, and subscriber management software. Backed by decades of wireless innovation and engineering expertise across 5G, Wi-Fi, antenna design, and cloud software, Inseego partners with mobile network operators worldwide to deliver connectivity at scale. Headquartered in San Diego, California, Inseego has offices in Amsterdam, Bangalore, and Athens. Learn more at www.inseego.com. 

Media Relations Contact:
pr@inseego.com 

Med virkning fra den 1. oktober 2026 offentliggøres prospekt for Investeringsforeningen Nordea Invest med ændringer i emissionstillæg og indløsningsfradrag for en række afdelinger, herunder andelsklasser.

Prospektet kan findes på https://www.nordeafunds.com/da/vores-fonde

Med venlig hilsen
Nordea Fund Management, filial af Nordea Funds Oy, Finland

Tim Galberg-Lund
Filialbestyrer

Hermed offentliggøres et ajourført prospekt for Secure Spectrum-afdelingerne i Investeringsforeningen Wealth Invest.

Prospektet er blevet ajourført som følge af en ændring i honorarstrukturen for porteføljeforvaltningshonoraret for så vidt angår afdeling Janus H High Yield Obligationer.

Prospektet er vedhæftet denne meddelelse og kan ligeledes tilgås via Foreningens hjemmeside.

For eventuelle spørgsmål kontakt Michael Frisch, direktør i foreningens investeringsforvaltningsselskab, på telefon 33 28 28 28.

Med venlig hilsen 

Investeringsforeningen Wealth Invest

Attachment

The new suite of OTC derivatives will help cotton market participants manage basis risk associated with non-US cotton exports

NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) — StoneX Markets LLC (“SXM”), a subsidiary of StoneX Group Inc. (NASDAQ: SNEX), has entered into an exclusive licensing agreement with Cotlook to launch a new suite of OTC cotton derivatives, designed to help market participants manage risk in an increasingly globalised cotton market. The first product developed under the partnership will be the Cotlook Brazil Basis Swap, a new risk management tool referencing Cotlook’s internationally recognised cotton pricing benchmarks.

The launch comes amid a major shift in global cotton trade flows. Brazil overtook the US as the world’s largest cotton exporter in the 2023/24 season, cementing its position as a key supplier to Asian textile manufacturers and an increasingly important influence on global pricing. As Brazil’s role has grown, so has the need for more effective risk management solutions.

The first OTC cotton derivative will reference the Brazilian component of the Cotlook A Index, helping farming cooperatives, merchants, mills, manufacturers and other cotton market participants better manage and hedge risk. Designed with the needs of the cotton supply chain in mind, it represents a significant enhancement to the tools available for managing price exposure.

Antonia Prescott, Managing Director and Editor, Cotlook, commented:

“The collaboration with StoneX is an important evolution in our longstanding mission to bring price transparency to the international cotton industry. We are pleased to be working with StoneX to create a valuable instrument for our customers to actively mitigate the full composition of their price risk.”

Brett Phillpott, Global Co-Head of Commercial Hedging & Commodities, StoneX, added:

“Our customers in the global cotton industry have long sought the ability to manage the basis risk inherent in their international cotton supply chains. These OTC derivatives will allow them to hedge a significant portion of their price risk that was previously unhedged.

“By working with Cotlook, we are enabling our clients to leverage a well-established benchmark to strengthen their risk management capabilities and improve forward price transparency for the market.”

About Cotlook

Cotlook Ltd is an independent UK-based company that has been engaged in publishing cotton prices, news and market analysis for over 100 years. It has a worldwide reputation for accuracy and impartiality, and its price information is trusted and used by government institutions in the US, China and elsewhere, as well as by international trading companies and other major cotton organisations. www.cotlook.com

About StoneX

StoneX Group Inc., through its subsidiaries, operates a global financial services network that connects companies, organisations, traders, and investors to the global market ecosystem through a unique blend of digital platforms, end-to-end clearing and execution services, high-touch service, and deep expertise. The company strives to be its clients’ trusted partner, providing its network, products, and services to help them pursue business opportunities, manage market risks, make informed investment decisions, and improve their business performance.

A Fortune 50 company headquartered in New York City and listed on the Nasdaq Global Select Market (NASDAQ: SNEX), StoneX Group Inc. and its more than 5,400+ employees serve over 80,000+ commercial, institutional, and payments clients, as well as more than 260,000 retail accounts, across more than 80 offices on six continents. Further information is available at www.stonex.com/en/

Media enquiries:

Marion Rannard, Senior Communications Specialist
marion.rannard@stonex.com
media@stonex.com

SNEX-G

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.